A Phase 4 interventional study of Valaciclovir and Placebo in Herpes Genitalis, sponsored by GlaxoSmithKline. Completed at 72 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing valacyclovir in Herpes Genitalis — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Genitalis.
Among the 14 studies testing valacyclovir in Herpes Genitalis, this one has the largest enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2004, is one of 6 in phase 4, and was the 7th registered.
70 studies on the registry are indexed under Herpes Genitalis; 3 are open to participants now.
Browse Herpes Genitalis studies →None of the 14 studies testing valacyclovir in Herpes Genitalis is open now. The open studies under Herpes Genitalis, anywhere →
Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →
Of the 1 Herpes Genitalis study recruiting now, none set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2004.
This study's enrollment of 384 is above the median of 103 across 51 interventional studies indexed under Herpes Genitalis.
Median enrollment 50 across the 11 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 6 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
11 studies in Herpes Genitalis by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 10 finished, 4 (40%) have results posted.
Among the 11 studies in Herpes Genitalis by GlaxoSmithKline, this one is one of 2 that started in 2004, is one of 4 in phase 4, and was the 7th registered.
GlaxoSmithKline’s Herpes Genitalis studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing valacyclovir in Herpes Genitalis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 11 in Herpes Genitalis:
This tab as a report to print or save as PDF → With an account.
Genital herpes (GH) is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are two types of HSV, type 1 (HSV-1) and type 2 (HSV-2); both can cause GH, although the latter is much more likely to produce frequent recurrences of GH lesions. Evidence suggests that there are advantages to using suppressive vs. episodic treatment, which include increased intervals between the pain and discomfort of genital herpes recurrences. Therefore, this study will collect safety and efficacy data on suppressive therapy with valaciclovir in subjects newly diagnosed with HSV-2 genital herpes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received double blinded treatment of oral dose of Valacyclovir 1 g given as 2 x 500 mg caplets QD for 6 months (24 weeks).
Drug: Valaciclovir
Participants received double blinded treatment of oral dose of matching placebo to Valacyclovir 1 gram (g) given as 2 x 500 milligram (mg) caplets once daily (QD) for 6 months (24 weeks).
Drug: Placebo
1g once daily
placebo
Percentage of Participants With Time to First GH Recurrence
Diary cards were issued to the participants during randomization visit for recording GH recurrences. HSV recurrences since the last visit was assessed after review of the diary card and discussion with the participant. The percentage of participants with time to first GH recurrence was based on Kaplan-Meier estimates. Confidence intervals for differences in proportions was calculated using the standard error for the Kaplan-Meier estimate derived using Greenwood's formula.
Time frame: Day 168
Mean Number of GH Recurrences Per Month Within the 6-month Study Period
Mean number of GH recurrence reaching macular/papular stage per month was reported. Diary cards were issued to the participants during randomization visit for the recording GH recurrences. HSV recurrences since the last visit was assessed after review of the diary card and discussion with the participant.
Time frame: Up to Day 168
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE was defined as any untoward medical occurrence that, at any dose results in death, was life-threatening, required hospitalization or prolongation of hospitalization, results in disability/incapacity, was a congenital anomaly/birth defect or medically significant.
Time frame: Upto Day 168
Percentage of Participants With Time to First Oral Herpes Simplex Virus (HSV) Outbreak Within 6-months
Diary cards were issued to the participants during randomization visit for recording HSV outbreak within 6-momths. HSV outbreak was assessed after review of the diary card and discussion with the participant. The percentage of participants who had first oral HSV outbreak at 6-months was reported.
Time frame: Day 168
Number of Isolates With Resistance to Acyclovir (ACV)
Culture samples were tested for AVC-susceptibility by the analytical laboratory. Re-testing of the ACV resistant isolates was carried out to check if the half maximal inhibitory concentration (IC-50s) for all the ACV resistant isolates were within the expected errors of 2.0 microgram per milliliters (mcg/ml) cut-off for the plaque reduction assay. Those isolates that confirm to be resistant in repeat assays were considered as resistant to ACV.
Time frame: Day 168
The study was conducted in 74 centers in the Unites States, Canada, Argentina, Brazil, and Chile.
| Milestone | Placebo | Valaciclovir 1g QD |
|---|---|---|
| Started | 128 | 255 |
| Completed | 93 | 184 |
| Not completed | 35 | 71 |
| Withdrew: Adverse event | 3 | 6 |
| Withdrew: Lost to follow-up | 11 | 17 |
| Withdrew: Protocol violation | 8 | 23 |
| Withdrew: Withdrawal by subject | 7 | 17 |
| Withdrew: Moving out of state | 1 | 0 |
| Withdrew: Pregnancy | 3 | 3 |
| Withdrew: Sponsor stopped study | 2 | 2 |
| Withdrew: Sponsor request | 0 | 1 |
| Withdrew: Lost to follow up but returned per gsk | 0 | 1 |
| Withdrew: Closed per sponsor | 0 | 1 |
Diary cards were issued to the participants during randomization visit for recording GH recurrences. HSV recurrences since the last visit was assessed after review of the diary card and discussion with the participant. The percentage of participants with time to first GH recurrence was based on Kaplan-Meier estimates. Confidence intervals for differences in proportions was calculated using the standard error for the Kaplan-Meier estimate derived using Greenwood's formula.
| Percentage of participants | Placebo | Valaciclovir 1g QD |
|---|---|---|
| Percentage of Participants With Time to First GH Recurrence | 43 | 71 |
Mean number of GH recurrence reaching macular/papular stage per month was reported. Diary cards were issued to the participants during randomization visit for the recording GH recurrences. HSV recurrences since the last visit was assessed after review of the diary card and discussion with the participant.
| Number of recurrences | Placebo | Valaciclovir 1g QD |
|---|---|---|
| Mean Number of GH Recurrences Per Month Within the 6-month Study Period | 0.48 ± 1.860 | 0.11 ± 0.254 |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE was defined as any untoward medical occurrence that, at any dose results in death, was life-threatening, required hospitalization or prolongation of hospitalization, results in disability/incapacity, was a congenital anomaly/birth defect or medically significant.
| Participants | Placebo | Valaciclovir 1g QD |
|---|---|---|
| Any AEs | 98 | 185 |
| Any SAEs | 4 | 3 |
Diary cards were issued to the participants during randomization visit for recording HSV outbreak within 6-momths. HSV outbreak was assessed after review of the diary card and discussion with the participant. The percentage of participants who had first oral HSV outbreak at 6-months was reported.
| Percentage of participants | Placebo | Valaciclovir 1g QD |
|---|---|---|
| Percentage of Participants With Time to First Oral Herpes Simplex Virus (HSV) Outbreak Within 6-months | 11 | 14 |
Culture samples were tested for AVC-susceptibility by the analytical laboratory. Re-testing of the ACV resistant isolates was carried out to check if the half maximal inhibitory concentration (IC-50s) for all the ACV resistant isolates were within the expected errors of 2.0 microgram per milliliters (mcg/ml) cut-off for the plaque reduction assay. Those isolates that confirm to be resistant in repeat assays were considered as resistant to ACV.
| Number of isolates | Placebo | Valaciclovir 1g QD |
|---|---|---|
| Number of Isolates With Resistance to Acyclovir (ACV) | 0 | 0 |
Collected over AEs were collected up to end of study (Day 168).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/128 (0%) | 4/128 (3.1%) | 75/128 (58.6%) |
| Valaciclovir 1g QD | 1/255 (0.4%) | 3/255 (1.2%) | 138/255 (54.1%) |
| Event | Placebo | Valaciclovir 1g QD |
|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 2/128 | 1/255 |
| HypokalaemiaMetabolism and nutrition disorders | 1/128 | 0/255 |
| LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/128 | 0/255 |
| AppendicitisInfections and infestations | 0/128 | 1/255 |
| Gun shot woundInjury, poisoning and procedural complications | 0/128 | 1/255 |
| Event | Placebo | Valaciclovir 1g QD |
|---|---|---|
| HeadacheNervous system disorders | 39/128 | 59/255 |
| NasopharyngitisInfections and infestations | 13/128 | 35/255 |
| Vulvovaginal mycotic infectionInfections and infestations | 12/128 | 16/255 |
| Herpes simplexInfections and infestations | 8/128 | 22/255 |
| DysmenorrhoeaReproductive system and breast disorders | 11/128 | 16/255 |
| NauseaGastrointestinal disorders | 10/128 | 11/255 |
| Urinary tract infectionInfections and infestations | 9/128 | 7/255 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 4/128 | 14/255 |
| InfluenzaInfections and infestations | 7/128 | 7/255 |
| Back painMusculoskeletal and connective tissue disorders | 6/128 | 13/255 |
| Age, Continuous(Years) | Placebo | Valaciclovir 1g QD | Total |
|---|---|---|---|
| Mean | 32.2 ± 11.52 | 30.9 ± 10.48 | 31.3 ± 10.84 |
| Sex: Female, Male(Participants) | Placebo | Valaciclovir 1g QD | Total |
|---|---|---|---|
| Female | 92 | 176 | 268 |
| Male | 36 | 79 | 115 |
| Race/Ethnicity, Customized(Participants) | Placebo | Valaciclovir 1g QD | Total |
|---|---|---|---|
| Race — American Hispanic | 17 | 34 | 51 |
| Race — Arabic/North African | 0 | 2 | 2 |
| Race — Black | 39 | 84 | 123 |
| Race — East & South East Asian | 0 | 2 | 2 |
| Race — White/Caucasian | 68 | 125 | 193 |
| Race — Unknown | 4 | 8 | 12 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Jun 2004 to primary completion in Jul 2006, 25 months.
Results were first posted in Feb 2019, 12 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valacyclovir